

Oral AMT Market Characteristics in Myanmar: ACTwatch Findings 2015

2001: Emergence of artemisinin resistance on Thai-Myanmar border

2010: Plan to reduce morbidity/mortality by 60% by 2016

2010: NMCP/DMR procurement of RDTs & QAACts

2011: MARC framework developed in response to resistance

2012: AL, DHA-PPQ, ASMQ are 1st-line treatment for Pf


2012: Roll-out of the AMTR program to rapidly replace oral AMT with QAACT

2014: Observance of artemisinin resistance along the India- & China-Myanmar borders

2016: AL is 1st-line treatment for Pf; DHA-PPQ & ASMQ are 2nd-line


Location of oral AMT found

Oral AMT was found in over 80% of townships in 2015




Market Share of oral AMT:

Distribution of oral AMT comprised 15% of the antimalarial market nationally; of all oral AMT distributed, 80% was **Artesunate®**.




Oral AMT characteristics:

Oral AMT products were manufactured in Vietnam, China, or in Myanmar. The most common oral AMT found was Artesunate® manufactured by Mediplantex in Vietnam.




15% of oral AMT products audited were expired; over 60% of oral AMT products had a shelf life of greater than two years.



Distribution of oral AMT:

One in four oral AMT-stocking outlets reportedly distributed the drug in the past week.



Distribution of less than a full-course was very common. This sub-optimal dosing is well below the recommended adult equivalent treatment dose of approximately 20 tablets.

2 tablets of oral AMT were typically dispensed to treat an adult, and sold for \$0.36

